source
- Novartis' $12B Avidity deal falters as DM1 therapy misses Phase 3 endpointNovartis' recent acquisition of Avidity Biosciences was intended to bring a novel therapy for Myotonic dystrophy type 1 (DM1) into its portfolio. The drug, del-desiran, an antibody-oligonucleotide…
- Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic diseaseNovo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…